- Co-amilozide
-
Co-amilozide Combination of Amiloride Potassium-sparing diuretic Hydrochlorothiazide Thiazide diuretic Clinical data AHFS/Drugs.com International Drug Names Pregnancy cat. ? Legal status POM (UK) Routes Oral Identifiers ATC code C03EA01 PubChem CID 107748 ChemSpider 96911 (what is this?) (verify) Co-amilozide (BAN) is a non-proprietary name used to denote a combination of amiloride and hydrochlorothiazide. Co-amilozide is used in the treatment of hypertension and congestive heart failure with the tendency of the thiazide to cause low potassium levels (hypokalaemia) offset by the potassium-sparing effects of amiloride.
Formulation
Two strengths of co-amilozide are currently available in the UK:[1]
- 2.5 mg amiloride and 25 mg hydrochlorothiazide, BAN of Co-amilozide 2.5/25 (brand name Moduret 25)
- 5 mg amiloride and 50 mg hydrochlorothiazide, BAN of Co-amilozide 5/50 (brand name Moduretic)
In North America:
- Moduretic (U.S., Canada)
- Moduretic 5-50 (U.S., Canada)
- Novamilor (Canada)
Side effects
The most common side effect is headache (about 8% of people taking it) and nausea, loss of appetite, weakness, rash and dizziness (each about 3%).[2]
Common side effects (1/10 - 1/100) include:[2]
- General: Weakness, fatigue, loss of appetite. Headache, dizziness.
- Circulatory system: Arrhythmia.
- Gastrointestinal: Nausea, diarrhea, abdominal pain.
- Skin: Exanthema, itching.
- Respiratory system: dyspnoea, cough.
- Metabolic.: Hyperglycemia in diabetic patients, hyperuricemia.
- Musculoskeletal.: Pain in the limbs.
References
- ^ British National Formulary 54 September 2007
- ^ a b the Swedish official drug catalog > Normorix Retrieved on Mars 30, 2010
Sympatholytic (and closely related) antihypertensives (C02) Sympatholytics
(antagonize α-adrenergic
vasoconstriction)CentralAdrenergic release inhibitorsBethanidine • Bretylium • Debrisoquine • Guanadrel • Guanazodine • Guanethidine • Guanoclor • Guanoxan • Guanazodine • Guanoxabenz • GuanoxanImidazoline receptor agonistMecamylamine • Pentolinium • TrimethaphanPeripheralIndirectTyrosine hydroxylase inhibitorDirectNon-selective α blockerOther antagonists Endothelin antagonist (for PH)#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.